drugset / Trial / NCT02598011
A Study of the Safety of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Newly Diagnosed High Grade Glioma Receiving Standard of Care
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a multi-center, open label trial of combination therapy with Toca 511 and ascending doses of Toca FC added to the SOC for newly diagnosed HGG.
Timeline
- Start
- 2017-01
- Primary completion
- 2022-11
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Flucytosine | Small molecule | 170 mg/kg | Oral |
| Subject | Flucytosine | Small molecule | 220 mg/kg | Oral |
| Subject | Vocimagene Amiretrorepvec | Unknown | 4 ml | Other |